Loading
A spindle-cell change found in about 10% of kidney cancers that makes them aggressive and, unexpectedly, unusually responsive to immunotherapy.
Sarcomatoid RCC (any histology) has median survival under a year on TKIs alone, but in CheckMate 214 nivolumab-ipilimumab produced ORR ~60% and complete responses in ~20%, with OS HR ~0.45. High PD-L1 and immune infiltration explain the paradox. Guidelines favour IO-based regimens in sarcomatoid disease.
Backbone ribbon from PDB 5WT9. RCSB PDB 5WT9. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
Showing the molecule this term concerns: Nivolumab.
Shares CheckMate 214, Ipilimumab, Nivolumab.
Shares CheckMate 214, IMDC risk → first-line regimen choice (RCC), Renal cell carcinoma.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares CheckMate 214, Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab.
Shares Ipilimumab, Nivolumab.